EGFR and chronic obstructive pulmonary disease: As active EGFR mutation is the critical factor to predict the response and survival outcome for patients that underwent EGFR-TKI treatment, it is unsurprisingly that COPD patients might had poor treatment efficacy on EGFR-TKI because of inherited low EGFR mutation frequency [24].